Kodiak Sciences says Zenkuda meets primary endpoint in Phase 3 DAYBREAK wet AMD trial

By Public Technologies
  • Kodiak Sciences reported pivotal Phase 3 DAYBREAK trial success in wet age-related macular degeneration for Zenkuda and tabirafusp-ted.
  • Both treatments matched aflibercept on vision outcomes at one year, supporting a potential path toward first-line use.
  • Zenkuda showed rapid disease control with longer dosing intervals for many patients, strengthening its commercial positioning versus standard anti-VEGF therapy.
  • The company plans a multi-indication Zenkuda BLA submission in 4Q2026, anchored by five positive Phase 3 studies.
  • Detailed DAYBREAK results will be presented at a company Webex on Sept. 28, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609280630PR_NEWS_USPR_____SF57778) on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.